ongoing studies in cml: investigating asciminib toxicity and improving tfr rates
Published 1 year ago • 296 plays • Length 1:24Download video MP4
Download video MP3
Similar videos
-
1:03
phase i study of asciminib in patients with cp-cml carrying the t315i mutation
-
6:31
an overview of trials investigating asciminib in the treatment of ph cml
-
1:16
mechanisms of resistance to the tki asciminib in cml
-
1:10
tolerability of bosutinib vs asciminib in heavily pre-treated patients with cml
-
3:26
asciminib: overcoming tki resistance and reducing toxicity in cml
-
0:58
asciminib has the potential to succeed where other tkis have failed in cml
-
2:12
key emerging trials in cml and the importance of improving treatment-free remission rates
-
1:35
asc2escalate: dose escalation study of asciminib in second-line cp-cml
-
8:00
jorge cortes, md, shares data on asciminib versus tkis in cml
-
7:24
primary antibody deficiency - common variable immunodeficiency (cvid) , x-linked agammaglobulinemia
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
1:46
asciminib versus other tkis in the frontline treatment of cml: the asc4first study
-
3:20
the current standard of care in cml and insights into the use of first- and second-generation tkis
-
1:13
the allg cml13 ascend-cml study: high major molecular responses with asciminib treatment for cp-cml
-
0:48
asciminib for the treatment of cml
-
1:08
managing drug resistance in cp-cml with ponatinib and asciminib
-
2:27
ascembl: asciminib versus bosutinib in third-line treatment of cp-cml
-
2:40
targeting tki-resistant cml with ly3009120 and asciminib
-
1:17
ponatinib versus ascimininib in the third-line treatment of cml
-
2:43
asciminib in newly diagnosed cml | nejm
-
1:15
the diagnosis and management of mds/mpn with neutrophilia (atypical cml)
-
1:53
asc2escalate: phase ii dose-escalation study of second-line asciminib in patients with cml-cp